Molecular imaging has great potential to become a valuable tool in this new era of “personalized and precision medicine.” Important steps in adapting a new “image and treat” strategy in HER2-positive and MUC1-positive breast cancer have already been initiated. This evidence concerns the gene MUC1 and breast cancer.